Axogen appoints William Burke to Board of Directors, effective July 11, 2022

Axogen, Inc.

William Burke, former EVP & CFO of Haemonetics, appointed as director effective July 11, 2022.
Burke will chair the Audit Committee; board committees were reconstituted.
Burke brings 25+ years of finance leadership from Medtronic, Covidien, and Haemonetics.
Compensation includes $10,000 quarterly retainer, $5,000 as Audit Committee chair, plus equity grants.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Burke

Director

AXGN · Axogen, Inc.

Effective: 2022-07-11
Filed: July 11, 2022, 7:59 PM ET

On July 8, 2022, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) appointed William Burke as a new director to fill the vacant directorship on the Board, effective July 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William Burke was appointed as Director at Axogen, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 8, 2022, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) appointed William Burke as a new director to fill the vacant directorship on the Board, effective July 11, 2022.

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-025652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.